Chavan Balasaheb B, Kalariya Pradipbhai D, Tiwari Shristy, Nimbalkar Rakesh D, Garg Prabha, Srinivas R, Talluri M V N Kumar
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education & Research, IDPL R&D Campus, Balanagar, Hyderabad, 500 037, India.
National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S., Nagar, 160 062, Punjab, India.
Rapid Commun Mass Spectrom. 2017 Dec 15;31(23):1974-1984. doi: 10.1002/rcm.7982.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) used for the treatment of major depressive disorder (MDD). An extensive literature search found few reports on the in vivo and in vitro metabolism of vilazodone. Therefore, we report a comprehensive in vivo and in vitro metabolic identification and structural characterization of vilazodone using ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry (UPLC/Q-TOF/MS/MS) and in silico toxicity study of the metabolites.
To identify in vivo metabolites of vilazodone, blood, urine and faeces samples were collected at different time intervals starting from 0 h to 48 h after oral administration of vilazodone to Sprague-Dawley rats. The in vitro metabolism study was conducted with human liver microsomes (HLM) and rat liver microsomes (RLM). The samples were prepared using an optimized sample preparation approach involving protein precipitation followed by solid-phase extraction. The metabolites have been identified and characterized by using LC/ESI-MS/MS.
A total of 12 metabolites (M1-M12) were identified in in vivo and in vitro matrices and characterized by LC/ESI-MS/MS. The majority of the metabolites were observed in urine, while a few metabolites were present in faeces and plasma. Two metabolites were observed in the in vitro study. A semi-quantitative study based on percentage counts shows that metabolites M11, M6 and M8 were observed in higher amounts in urine, faeces and plasma, respectively.
The structures of all the 12 metabolites were elucidated by using LC/ESI-MS/MS. The study suggests that vilazodone was metabolized via hydroxylation, dihydroxylation, glucuronidation, oxidative deamination, dealkylation, dehydrogenation and dioxidation. All the metabolites were screened for toxicity using an in silico tool.
维拉唑酮是一种用于治疗重度抑郁症(MDD)的选择性5-羟色胺再摄取抑制剂(SSRI)。广泛的文献检索发现关于维拉唑酮体内和体外代谢的报道很少。因此,我们报告了使用超高效液相色谱/四极杆飞行时间串联质谱(UPLC/Q-TOF/MS/MS)对维拉唑酮进行的全面体内和体外代谢鉴定及结构表征,以及对代谢物的计算机毒性研究。
为了鉴定维拉唑酮的体内代谢物,在给Sprague-Dawley大鼠口服维拉唑酮后,从0小时到48小时的不同时间间隔收集血液、尿液和粪便样本。体外代谢研究使用人肝微粒体(HLM)和大鼠肝微粒体(RLM)进行。样本采用优化的样本制备方法,包括蛋白质沉淀,然后进行固相萃取。代谢物通过LC/ESI-MS/MS进行鉴定和表征。
在体内和体外基质中总共鉴定出12种代谢物(M1-M12),并通过LC/ESI-MS/MS进行了表征。大多数代谢物在尿液中被观察到,而少数代谢物存在于粪便和血浆中。在体外研究中观察到两种代谢物。基于百分比计数的半定量研究表明,代谢物M11、M6和M8分别在尿液、粪便和血浆中含量较高。
使用LC/ESI-MS/MS阐明了所有12种代谢物的结构。该研究表明维拉唑酮通过羟基化、二羟基化、葡萄糖醛酸化、氧化脱氨、脱烷基化、脱氢和二氧化作用进行代谢。使用计算机工具对所有代谢物进行了毒性筛选。